Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Omnicell, Inc. (“Omnicell” or the “Company”) (NASDAQ:OMCL) concerning possible violations of federal securities laws. The investigation is focused on the Company’s operations and financial performance.

Please contact Lesley Portnoy or Casey Sadler at (888) 773-9224 or (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

Omnicell provides automation and business information solutions designed to enable hospitals and long-term healthcare facilities to acquire, manage, dispense and administer medications and medical-surgical supplies. The investigation is related to the Company’s March 2, 2015, disclosure in a regulatory filing that Omnicell is unable to timely file its Annual Report on Form 10-K for the year ended December 31, 2014, and intends to file the Form 10-K within fifteen calendar days of the original due date.

According to the Company, “additional time is required by the Company to investigate a notice received on February 27, 2015 from a Company employee alleging, among other matters, the existence of a ‘side letter’ arrangement with a Company customer for certain discounts and Company products that were to be provided at no cost, but which were not reflected in the final invoices paid by the customer.” Following this news, Omnicell shares fell as much as $2.33 per share, or more than 6.6%, during intraday trading on March 3, 2015.

If you purchased Omnicell securities, if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, or Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at (310) 201-9150, Toll Free at (888) 773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.